ArticleBMC cancer2025
The association of metabolic disorders and prognosis in cancer patients.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of different exercise prescription parameters on metabolic and inflammatory biomarkers in cancer patients: a systematic review, meta-analysis, and meta-regression.Frontiers in immunology · 2025Pooled it
- Integration of objective nutritional status and tumor burden predicts 5-year survival after gastric cancer surgery: a multicenter real-world study.Surgical endoscopy · 2026Article
- Observational
- Observational
- Association between human herpesvirus 6 status and sarcopenia risk: a UK biobank cohort study with sex-specific patterns and telomere length modification.Frontiers in immunology · 2025Article
- The atherogenic index of plasma and triglyceride-glucose index as promising predictors of overall and disease-free survival in postoperative breast cancer patients.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetabolic disorders are common in cancer patients. This study aimed to classify the metabolic disorder status of cancer patients using hematological indicators and to examine the association between disorder types and prognosis.
methodsA cohort of 6307 patients from INSCOC was classified into three clusters via K-means clustering based on hematological indicators. Logistic regression and Cox models assessed each cluster's impact on adverse outcomes.
resultsA total of 6,307 participants were included in the study, K-means clustering divided the population into three groups, Cluster 1 (Normal Group, NG), Cluster 2 (Mild Disorder Group, MDG) and Cluster 3 (Severe Disorder Group, SDG). Compared to NG, MDG (OR = 2.268; 95% CI: 1.967-2.616) and SDG (OR = 4.317; 95% CI: 2.441-7.634) had significantly higher risks of sarcopenia. MDG (OR = 1.943; 95% CI: 1.717-2.198) was associated with a higher risk of moderate malnutrition, and both MDG (OR = 3.786; 95% CI: 3.282-4.368) and SDG (OR = 14.501; 95% CI: 6.847-30.709) were identified as risk factors for severe malnutrition (p < 0.05). Cox regression analysis indicated that MDG and SDG were independent risk factors for all-cause mortality (MDG: HR = 1.460, 95% CI: 1.341-1.590; SDG: HR = 2.257, 95% CI: 1.622-3.140) and cancer-specific mortality (MDG: HR = 1.192, 95% CI: 1.039-1.367; SDG: HR = 2.068, 95% CI: 1.825-2.343) (p < 0.05).
conclusionK-means clustering effectively categorized metabolic disorder subgroups, supporting targeted interventions and demonstrating a significant link between disorder severity and adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.